Aspira Women's Health
Aspira Women's Health Licenses Dana-Farber microRNA Signature; Firm Executes Reverse Stock Split
Aspira Women's Health has been evaluating Dana-Farber's microRNA technology for ovarian cancer detection since early 2021.
Aspira Women's Health Prices $9M Public Offering
The company is offering 12 million shares of common stock along with warrants to purchase 12 million shares.
Earnings Roundup: DermTech, 908 Devices, OraSure, Codex DNA, Aspira, IsoPlexis, Epigenomics
DermTech, 908 Devices, OraSure Technologies, Codex DNA, Aspira Women's Health, and Epigenomics reported quarterly financial results this week.
Biodesix, Sera Prognostics, Aspira, Epigenomics Post Q1 Financial Results
All four companies posted net losses for the quarter, while Biodesix's results were hit by a sharp decline in COVID-19 testing revenue.
Aspira Q4 Revenues up 36 Percent
The company reported total revenues of $1.9 million, up from $1.4 million in Q4 2020, while sales of its OVA1plus test were up 23 percent.